Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth in 2025?
The market size for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) has seen an exponential growth in recent years. The market, valued at $2.00 billion in 2024, is projected to increase to $2.60 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 30.0%. This significant growth observed in the historical period is associated with the increased occurrence of non-alcoholic steatohepatitis, modern dietary trends featuring high-processed food intake, sedentary living conditions, and an escalated prevalence of metabolic disorders.
What Is the Forecast for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Through 2029?
The market for metabolic dysfunction-associated steatohepatitis (MASH) treatment is anticipated to witness an exponential surge in the coming years. The market is forecasted to reach a valuation of $7.38 billion in 2029, growing at a compound annual growth rate (CAGR) of 29.8%. This growth during the outlook period is chiefly driven by the rising incidences of obesity and diseases related to it, early treatments, reimbursement strategies, insurance provisions, and increased knowledge about liver ailments. During the prediction period, advancements in technology, progress in the pipeline, strategic alliances and partnerships, customised medicine and precision treatments, and investment in clinical trials and research are expected to be the key trends.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
What are the Key Market Players in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market and How They’re Evolving?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
What Are the Primary Growth Drivers in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The rising instances of obesity are anticipated to fuel the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market. Obesity, identified by an excessive build-up of body fat that adversely affects overall health, is typically gauged by a body mass index (BMI) of 30 or above. Sedentary lifestyles, unhealthy eating habits, and metabolic risk factors are causing obesity rates to escalate worldwide. When it comes to treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) in obese patients, the focus is on managing insulin resistance, decreasing liver fat, and enhancing metabolic health via lifestyle modifications and specific therapies. For instance, as stated by the World Heart Foundation, a Switzerland-based non-government global cardiovascular community, in March 2023, about 2.3 billion adults and children around the world are either overweight or obese. This figure, fueled by the continuing rise in obesity, is expected to hit 2.7 billion by 2025. Consequently, the escalating instances of obesity are contributing significantly to the growth of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
What Are the Leading Segments in the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
What Are the Key Market Trends in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry?
Key players in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are concentrating their efforts on creating innovative products, including liver fibrosis treatments, to provide care options for patients with MASH and moderate to severe liver fibrosis. Solutions for liver fibrosis tackle the root causes of liver damage, promoting lifestyle changes, antiviral drugs, and cutting-edge antifibrotic treatments, with the goal of halting or reversing fibrosis and enhancing liver function. To illustrate, in March 2024, Madrigal Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, publicized the FDA’s endorsement of Rezdiffra (resmetirom), a pioneering treatment for MASH with moderate to severe liver fibrosis. Rezdiffra, an oral tablet taken once daily, exhibited its effectiveness in resolving MASH without intensifying fibrosis and in improving liver fibrosis during phase 3 clinical studies. This advancement provides a non-invasive treatment option, making liver biopsies unnecessary and considerably enhancing patient access and results in the management of fatty liver disease.
Access The Full Report Here:
What Is the Regional Outlook for the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876
This Report Delivers Insight On:
1. How big is the metabolic dysfunction-associated steatohepatitis (mash) treatment market, and how is it changing globally?
2. Who are the major companies in the metabolic dysfunction-associated steatohepatitis (mash) treatment market, and how are they performing?
3. What are the key opportunities and risks in the metabolic dysfunction-associated steatohepatitis (mash) treatment market right now?
4. Which products or customer segments are growing the most in the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
5. What factors are helping or slowing down the growth of the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
